Genomic characterization of SARS-CoV-2 strains isolated from COVID-19 cases indicates decreased neutralization efficacy of anti-SARS-CoV-2 monoclonal antibodies (mAb), convalescent plasma (CP), and vaccine-derived plasma (VP) against these variants [12,13,14]. This evidence concerns the gene CP and COVID-19.